CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Applied Neurosolutions Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Applied Neurosolutions Inc
Suite 111, 50 Lakeview Parkway
Phone: (847) 573-8000p:847 573-8000 VERNON HILLS, IL  60061  United States Ticker: APNS APNS

On 10/01/2014, the U.S. Securities and Exchange Commission revoked the registration of each class of registered securities of Applied Neurosolutions Inc. for failure to make required periodic filings with the Commission.
This company is no longer actively traded on any major stock exchange.

Business Summary
Applied NeuroSolutions, Inc. (APNS) is a development-stage biotechnology company focused on the development of products for the early diagnosis and treatment of Alzheimer's disease (AD or Alzheimer’s). Alzheimer’s disease is the cause of dementia among people age 65 and older. APNS is focused on developing serum-based tests to detect AD at an early stage in the disease process. In July 2009, the Company announced it had achieved feasibility in its development of a serum-based test related to the diagnosis of patients with AD and provided an update in October 2009. The Company’s focus is on advancing the development of a blood-based test for AD to commercialization. APNS has developed a cerebrospinal fluid (CSF)-based test that can detect AD at an early stage, as well as identify patients with mild cognitive impairment (MCI) who are likely to progress to AD.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/201012/31/2009YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Ellen R.Hoffing 53 8/31/2009 8/29/2006
Director David C.Tiemeier 63 9/1/2009 10/23/2007
Director Edward A.Ogunro 57 10/30/2008 10/30/2008
Director Gary C.Parks 59 11/14/2008 11/14/2008

General Information
Number of Employees: 3 (As of 3/5/2010)
Outstanding Shares: 4,404,375 (As of 6/8/2010)
Shareholders: 2,100
Stock Exchange: OTC
Federal Tax Id: 391661164
Fax Number: (302) 655-5049


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023